This Week in Allergy & Immunology — Jun 20, 2026

Welcome to This Week in Allergy and Immunology. This week we are covering ten notable papers spanning new paradigms in chronic airway disease remission, advanced insights into pediatric asthma and molecular immunology, and novel on-demand therapeutic strategies for hereditary angioedema, food allergy, and urticaria. Let us dive in.

Our first theme focuses on a paradigm shift in how we conceptualize and treat chronic airway diseases, moving from symptom control to achieving clinical remission. A landmark consensus paper from the European Forum for Research and Education in Allergy and Airway Diseases, or EUFOREA, published in the journal Allergy, outlines practical guidance for inducing and maintaining remission across global airway diseases [7]. An international panel of experts convened in Rome to establish key principles, emphasizing that clinical remission is a realistic therapeutic target regardless of how severe the disease was before starting treatment. The panel reached a consensus that chronic rhinosinusitis with nasal polyps accompanied by nonallergic eosinophilic asthma, as well as allergic rhinitis accompanied by allergic asthma, should be treated as features of a single global airway disease rather than separate comorbidities. While each specialty should assess remission criteria independently, they must coordinate on combined therapeutic approaches. The consensus recommends pragmatic definitions to ensure clinical utility, suggesting a four-week recall window to assess symptom control and a minimum twelve-month period to formally define sustained clinical remission. This clinical push for disease-modifying therapies is supported by new insights into the cellular biology of severe airway disease. In a study also published in Allergy, researchers investigated the role of accelerated biological aging in severe asthma [3]. Utilizing transcriptomic data from the U-BIOPRED cohort and validating their findings in the independent NOVA cohort, the authors evaluated the enrichment of cellular senescence pathways in the airways. They discovered that p53 and senescence-associated secretory pathways were significantly elevated in the bronchial biopsies of patients with severe asthma compared to those with mild-to-moderate asthma or healthy controls. Higher senescence scores in bronchial tissues correlated with frequent exacerbations, oral corticosteroid use, comorbid nasal polyps, and lower lung function. Interestingly, these senescence signatures correlated positively with oxidative phosphorylation and macrophage activation signatures, but not with eosinophil signatures, suggesting that non-eosinophilic, age-related tissue remodeling plays a major role in severe asthma pathology. When evaluating patients with refractory asthma, clinicians must also remain vigilant for mimicking or coexisting conditions. An algorithmic review published in Allergy addresses the diagnosis of concomitant inducible laryngeal obstruction in adults with asthma [1]. Implementing a structured diagnostic algorithm is essential to differentiate between laryngeal closure and true asthma exacerbations, helping to avoid inappropriate medication escalation and guide targeted speech therapy or behavioral interventions.

Turning to pediatric asthma and the underlying mechanisms of type 2 inflammation, a post-hoc analysis of the phase three VOYAGE trial published in The Journal of Allergy and Clinical Immunology: In Practice evaluated the efficacy of dupilumab in children aged six to eleven with uncontrolled, moderate-to-severe, type 2 asthma [4]. The analysis stratified three hundred and thirty-six children by their baseline allergen sensitization status: twenty-two percent were non-sensitized, seventeen percent were monoallergen sensitized, and sixty percent were multiallergen sensitized. Dupilumab, administered every two weeks, reduced annualized severe asthma exacerbations by seventy-five percent in the mono-sensitized group and by sixty percent in the multiallergen-sensitized group compared to placebo, both of which were highly statistically significant. In the non-sensitized subgroup, dupilumab led to a forty-five percent reduction in exacerbations, which was a numerical improvement but did not reach statistical significance. Importantly, children across all three subgroups showed comparable, significant improvements in lung function, asthma control scores, and total immunoglobulin E levels, demonstrating that dupilumab provides broad clinical benefits regardless of specific allergic sensitization. To better understand the cellular drivers of such type 2 immune responses, a basic science paper in The Journal of Allergy and Clinical Immunology explored the molecular biology of group two innate lymphoid cells, or ILC2s [6]. A specific subset of these cells expressing the KIT receptor, also known as CD117, has been linked to severe asthma and psoriasis due to their high phenotypic plasticity. Using single-cell transcriptomics and epigenomic profiling, researchers discovered that KIT-positive ILC2s maintain a unique hybrid character, expressing genes associated with both multipotent lymphoid precursors and mature ILC2s. Their epigenome is primed at gene loci related to naive lymphocyte biology and ILC3 effector functions, including interleukin-17 and the interleukin-23 receptor, explaining why these cells are uniquely poised to adopt an inflammatory, ILC3-like state. Genetic risk variants for asthma and autoimmune diseases were highly enriched in this poised epigenome. Furthermore, the study identified that the common gamma-chain cytokines interleukin-2 and interleukin-7 induce and maintain this plastic, precursor-like state through the activation of the STAT5 transcription factor, pointing to STAT5-mediated cytokine signaling as a promising therapeutic target to curb pathological cell plasticity in severe allergic diseases.

Our third theme highlights rapid-acting, targeted interventions that address acute symptoms in hereditary angioedema, food allergy, and chronic urticaria. In The World Allergy Organization Journal, a pooled analysis of phase two and phase three clinical trials evaluated sebetralstat, an investigational oral plasma kallikrein inhibitor, for the on-demand treatment of hereditary angioedema attacks [2]. Modern guidelines encourage early treatment of attacks without waiting for symptoms to become severe. This pooled analysis included three hundred and seventy-seven attacks, where the median time from attack onset to oral treatment was just thirty-two and a half minutes. Compared to placebo, sebetralstat significantly accelerated the beginning of symptom relief, the reduction in attack severity, and complete attack resolution. The median time to the beginning of symptom relief was under two hours—specifically one point six hours for the three hundred milligram dose and one point eight hours for the six hundred milligram dose—compared to over eight hours in the placebo group. Sebetralstat was well tolerated with a safety profile comparable to placebo, supporting its potential as a convenient and rapid oral on-demand therapy. In another effort to improve acute symptom relief, the INSPIRE trial, published in The Journal of Allergy and Clinical Immunology: In Practice, investigated an innovative approach for managing acute, IgE-mediated abdominal pain during food allergy reactions [8]. Abdominal pain is a frequent and distressing symptom during oral food challenges or oral immunotherapy, and acute treatment options are limited. Because the short-acting beta-agonist salbutamol can relax gastrointestinal smooth muscle, researchers conducted a double-blind, randomized, placebo-controlled trial comparing eight hundred micrograms of inhaled salbutamol to placebo in patients aged six to fifty-five who developed moderate-to-severe abdominal pain. Although the trial was terminated early due to slow recruitment, the results from the twenty-four randomized participants were striking. The median time to patient-perceived adequate analgesia was just six minutes in the salbutamol group, whereas it was not reached within the thirty-minute study window in the placebo group. Similarly, complete resolution of abdominal pain occurred in a median of ten minutes with salbutamol and was not reached in the placebo group. While these findings require confirmation in larger trials, they suggest that inhaled salbutamol could serve as a rapid, accessible tool for managing food-induced gastrointestinal cramping. For patients suffering from chronic spontaneous urticaria, the Annals of Allergy, Asthma, and Immunology published a pooled analysis of the phase three REMIX-1 and REMIX-2 trials evaluating remibrutinib [10]. Remibrutinib is an oral, highly selective Bruton's tyrosine kinase inhibitor evaluated in over nine hundred adults who remained symptomatic despite receiving second-generation H1-antihistamines. Within just one week of starting remibrutinib, patients experienced substantial, clinically meaningful improvements in urticaria activity and sleep interference compared to placebo. These benefits, along with improvements in overall quality of life and work productivity, were sustained through fifty-two weeks of treatment, and patients who transitioned from placebo to remibrutinib at week twenty-four achieved similar rapid improvements, establishing remibrutinib as a highly effective oral option for refractory urticaria.

Our final theme addresses clinical considerations at opposite ends of the age spectrum: pediatric allergy prevention and geriatric rhinitis. A review in Allergy examines the role of emollient formulations and skin barrier practices in preventing atopic dermatitis and the subsequent progression of the atopic march toward food allergy [9]. While early, prophylactic emollient use was initially seen as a straightforward prevention strategy, recent large-scale trials have shown conflicting results. The authors explain that the skin is a dynamic, living barrier, and that generic emollient use can sometimes backfire. Improperly formulated emollients—particularly those containing food-derived ingredients like oat or nut oils, haptens, or irritants—or improper application techniques can disrupt the skin barrier and inadvertently promote transcutaneous allergen sensitization. The review advocates for a shift toward a precision-based, barrier-directed approach, utilizing optimized formulations that restore the physiological lipid composition and integrating objective biomarkers to guide early, individualized interventions. On the other end of the lifespan, managing rhinitis in older adults presents unique diagnostic and therapeutic challenges. A collaborative paper with the ARIA guidelines, published in The Journal of Allergy and Clinical Immunology: In Practice, highlights that allergic rhinitis in the elderly is frequently intertwined with non-allergic rhinitis, compounded by age-related structural changes like nasal dryness, congestion without clear triggers, and isolated rhinorrhea [5]. Diagnosis is often delayed or missed, and treatment is complicated by multimorbidity, frailty, and polypharmacy, which increases the risk of drug-drug interactions. The guidelines emphasize a critical safety message: first-generation oral antihistamines must be strictly avoided in older patients due to their severe systemic side effects, including anticholinergic effects and cognitive impairment. Instead, first-line management should rely on safer topical and second-generation therapies, including intranasal corticosteroids, second-generation oral antihistamines, intranasal H-antihistamines, or fixed-dose intranasal combinations.

If you only have time for one paper this week, make it the EUFOREA consensus paper on disease remission in global airway diseases, published in Allergy [7]. This paper is our top pick because it establishes a highly practical, multidisciplinary framework that elevates our clinical ambitions from simple symptom management to achieving true, long-term disease remission in patients with concurrent upper and lower airway disease.

Here are the key takeaways from this week in Allergy and Immunology. First, shift your clinical target from symptom control to formal disease remission in patients with chronic airway diseases, treating conditions like asthma, allergic rhinitis, and nasal polyps as a single global airway disease rather than separate comorbidities [7]. Second, when prescribing dupilumab for children with uncontrolled, moderate-to-severe, type two asthma, expect significant reductions in severe exacerbations and improvements in lung function, particularly in those with mono- or multiallergen sensitization [4]. Third, keep oral sebetralstat in mind as a highly effective, fast-acting oral on-demand treatment for hereditary angioedema attacks, which can provide initial symptom relief in under two hours [2]. Fourth, consider inhaled salbutamol as a rapid, off-label therapeutic option to relieve acute, IgE-mediated abdominal pain and cramping during food allergy reactions or oral immunotherapy [8]. And finally, when managing allergic rhinitis in elderly patients, avoid first-generation oral antihistamines entirely to prevent adverse drug effects, opting instead for intranasal corticosteroids, intranasal antihistamines, or second-generation oral antihistamines [5].

That is your roundup for This Week in Allergy and Immunology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.